Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » News » NECA/Ipsen Workshop: Improving NET Awareness & Time to Diagnosis

NECA/Ipsen Workshop: Improving NET Awareness & Time to Diagnosis

  • August 24, 2023
Workshop attendees

Pictured L to R: Warren Brooks (Ipsen), Nadia Navie (Ipsen), Meredith Cummins (NECA CEO), Brad McKenzie (NET patient), Zoë Teunissen (NECA Intern)

Brad McKenzie (NET patient & NECA Consumer Advisory Board member) and our CEO Meredith Cummins were invited to participate in a workshop with Ipsen Senior Staff to investigate awareness of NETs and ways we could expedite earlier diagnosis. 

The workshop objective was to identify mutual areas of interest and practical initiatives for NECA & Ipsen to collaborate on NET awareness and to decrease patients’ time to diagnosis.

The workshop commenced with Brad telling his story then we looked at who are the stakeholders involved in NETs. This included the patient, family, GP, Specialist and Employers to name a few. We identified the issues which can be experienced and the impact of a NETs diagnosis on all the stakeholders. We then brainstormed how we could improve time to diagnosis and what avenues to explore and then how Ipsen & NECA could work together to increase awareness in the general community and to healthcare professionals. 

We are very excited to explore and hopefully progress in this much needed area. We also included Zoe Teunissen (our Intern from The Netherlands) to join the workshop and share the work she has done in Europe and what she is planning to do with NECA, looking at communication and the impact of the NET Optimal Care Pathway.

Share this post

Recent posts

VHL Awareness Month 2025

May 6, 2025

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

May 5, 2025

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

April 29, 2025

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

April 5, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousPerth NET Forum Recap
NextHave your say on #EndGenderBias in Australia’s healthcare systemNext

Related Posts

VHL Awareness Month 2025

May is internationally recognised as Von Hippel-Lindau (VHL) Awareness Month—a time to highlight this rare genetic, and in some case not genetic, condition and the

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

NeuroEndocrine Cancer Australia (NECA) is proud to recognise the advocacy efforts of NET patient Chris Geljon, who has taken the time to raise awareness of

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

Jo O’Halloran was in her early fifties when the symptoms she and her friends had heard so much about started to appear. ‘I was always

Neuroendocrine Cancer in Budget 2025–26

The 2025–26 Federal Budget, delivered by the Treasurer Hon Jim Chalmers on 25th March, included a welcome investment of $256.2 million over four years from 2025–26 (and

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin